|
Carboplain is often used as part of a combination chemotherapy regimen.
Doctors select a combination of drugs, each of which has some
effectiveness against the target disease by itself. The two drugs
have different mechanisms – e.g. They aren't both alkylating agents
or antifolates. The organ system that gives out first when doses
are raised, for instance bone marrow, lungs, or kidneys – these
should be different between the two classes of drugs so high doses
of both can be given. Many combinations of chemotherapy agents
have been found to produce better success than the individual
components. Remission rates can be substantially higher. This
is the philosophy behind combination chemotherapy: combining drugs
with different mechanisms and different toxicities (dose-limiting)
can produce a bigger therapeutic effect at the maximum dosages
for the two drugs.
When docetaxel or paclitaxel are combined with carboplain, they
are administered first. This helps limit myelosuppression and
enhance cytotoxic efficacy.
|